- Report
- February 2025
- 184 Pages
Global
From €3426EUR$3,825USD£2,920GBP
€4031EUR$4,500USD£3,436GBP
- Report
- January 2025
- 182 Pages
Global
From €3426EUR$3,825USD£2,920GBP
€4031EUR$4,500USD£3,436GBP
- Report
- June 2024
- 183 Pages
Global
From €3426EUR$3,825USD£2,920GBP
€4031EUR$4,500USD£3,436GBP
- Report
- July 2024
- 70 Pages
Global
From €4255EUR$4,750USD£3,627GBP
- Report
- July 2024
- 70 Pages
Global
From €4255EUR$4,750USD£3,627GBP
- Report
- January 2025
- 140 Pages
Global
From €3538EUR$3,950USD£3,016GBP
- Report
- March 2025
- 1400 Pages
Global
From €3292EUR$3,675USD£2,806GBP
€4389EUR$4,900USD£3,741GBP
- Report
- February 2025
- 120 Pages
Global
From €3910EUR$4,365USD£3,333GBP
€4344EUR$4,850USD£3,703GBP
- Report
- March 2025
- 260 Pages
Middle East
From €1948EUR$2,175USD£1,661GBP
€2598EUR$2,900USD£2,214GBP
- Report
- March 2025
- 260 Pages
Africa
From €1948EUR$2,175USD£1,661GBP
€2598EUR$2,900USD£2,214GBP
- Report
- March 2025
- 210 Pages
Latin America
From €1948EUR$2,175USD£1,661GBP
€2598EUR$2,900USD£2,214GBP
- Report
- March 2025
- 840 Pages
Asia Pacific
From €1948EUR$2,175USD£1,661GBP
€2598EUR$2,900USD£2,214GBP
- Report
- March 2025
- 980 Pages
Europe
From €1948EUR$2,175USD£1,661GBP
€2598EUR$2,900USD£2,214GBP
- Report
- February 2025
- 236 Pages
United States
From €7161EUR$7,995USD£6,104GBP
- Report
- November 2023
- 127 Pages
Global
From €4031EUR$4,500USD£3,436GBP
- Report
- December 2022
- 66 Pages
Global
From €3135EUR$3,500USD£2,672GBP
- Report
- August 2023
- 336 Pages
Global
From €4165EUR$4,650USD£3,550GBP
- Report
- January 2023
- 127 Pages
Global
From €2015EUR$2,250USD£1,718GBP
- Report
- February 2020
- 237 Pages
Global
From €2463EUR$2,750USD£2,100GBP
- Report
- July 2023
- 220 Pages
Global
From €1782EUR$1,990USD£1,519GBP

The Glucagon Like Peptide 1 Agonist (GLP-1) market is a subset of the larger diabetes drugs market. GLP-1 agonists are a class of drugs used to treat type 2 diabetes, and are designed to mimic the effects of the hormone glucagon-like peptide-1 (GLP-1). GLP-1 agonists work by stimulating the release of insulin, reducing the amount of glucose in the blood, and slowing the rate of gastric emptying. GLP-1 agonists are typically administered via injection, and are used in combination with other diabetes medications.
The GLP-1 agonist market is highly competitive, with a number of major pharmaceutical companies offering products. These include Novo Nordisk, Eli Lilly, Sanofi, AstraZeneca, and Boehringer Ingelheim. Show Less Read more